Key Highlights

  • Revenue of USD 11.57 million beat the USD 11.33 million estimate, up 11%, with Earnings of USD 0.00 per share.
  • Gross Margin was 65.2% against 60.2% a year earlier, and Net Income was positive at USD 200,000.
  • Management raised the low end of 2026 Revenue guidance to USD 48 million to USD 48.5 million.
  • The company exited the quarter with USD 7.4 million in cash, with an unused USD 10 million Debt facility.

KORU Medical Systems (NASDAQ:KRMD), a maker of subcutaneous infusion systems, reported third quarter 2026 revenue of USD 11.57 million against a USD 11.33 million estimate, up 11% year over year. Earnings Per Share were USD 0.00 against an estimated loss of USD 0.02. Management said net income was positive at USD 200,000.

Management said revenue growth slowed in the third quarter as it had guided on its second quarter call. Domestic core revenue was USD 8.1 million, and normalized domestic core revenue grew about 10% while international core revenue grew 23% on new patient starts in existing markets. Pharma services and Clinical Trials revenue declined 27% on lower product orders for a customer's clinical trial program.

Margins and Profitability

Gross margin was 65.2% against 60.2% a year earlier, and year-to-date gross margin was 64%, up 190 basis points from 62.1%. Operating expenses as a percentage of sales fell from 70.2% to 64% for the nine months, an improvement of 620 basis points. Adjusted EBITDA for the nine months was USD 2.2 million against USD 100,000, and net loss for the period narrowed from USD 2.2 million to USD 300,000. Management noted positive net income in each of the last two quarters.

Guidance, Cash and Regulatory Items

Management raised the bottom end of full year 2026 revenue guidance to a range of USD 48 million to USD 48.5 million, representing 17% to 18% growth, from USD 47.5 million to USD 48.5 million. It anticipates positive adjusted EBITDA for the full year and raised its year-end cash balance target to above USD 8 million from USD 7.5 million.

The company exited the quarter with USD 7.4 million in cash after using USD 900,000, which management attributed entirely to Working Capital for inventory purchases supporting fourth quarter revenue acceleration and higher receivables. It has access to an unused USD 10 million debt Facility and anticipates positive Cash Flow in the fourth quarter.

Management also noted that its 510(k) application for deferoxamine remains under FDA review, and that endpoints for a secondary immunodeficiency pivotal trial are anticipated toward the end of 2027. It referred to Takeda's presentation of pivotal data on an investigational subcutaneous immunoglobulin 20% therapy, which the company said delivered the same dose in half the volume.

Items to Follow

The legal proceedings section of the quarterly filing did not identify a specific matter. The items to follow are fourth quarter revenue acceleration, international growth, pharma services orders and cash flow. Management said the third quarter slowdown was consistent with its prior guidance. It also said it is seeing revenue acceleration in the fourth quarter, with growth guided to the high teens for the quarter and the year.